ABSTRACT
AIM: To investigate the difference of cognitive impairment and depression between age-related macular degeneration ( AMD ) group and the control group patients. ·METHODS: A prospective case-control study was performed from November 2014 to August 2016 in the hospital for AMD patients and sex-matched control group. The Mini-Mental State Examination ( MMSE) and the Geriatric Depression Scale ( GDS ) score of each patient were collected for statistical analyzing. ·RESULTS: There were total 84 cases ( 168 eyes ) included in the study. The difference of visual acuity between the two group was statistically significant ( F=8. 953, P=0. 004) by baseline data analyzing. There were no significant differences in MMSE scores between the two groups according to educational status ( P>0. 05 ) , while the prevalence of cognitive impairment in each group was statistically significant (x2 =4. 14, P=0. 042). The difference of GDS scores, prevalence of total and mild depression between two groups were both statistically significant (F=5. 852, P=0. 018; x2=6. 372, P=0. 012; x2 = 5. 674, P = 0. 017 ). However, there was no statistically significant difference in the prevalence of moderate to severe depression (x2=0. 672, P=0. 412). ·CONCLUSION: AMD patients have a higher prevalence of depression. Although MMSE score differences were not statistically significant in subgroup analysis by educational levels, AMD patients are more likely to have cognitive impairment overall.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the combined effects between the two polymorphisms murine double minute 2 (MDM2) rs2279744 T→G and P53 rs1042522 G→C on the genetic susceptibility of breast cancer.</p><p><b>METHODS</b>A total of 600 female patients with diagnosed breast cancer were consecutively recruited from the Yuhang district, Hangzhou city during March 2001 to May 2009. In the same period as the cases were collected, 600 healthy women living in Yuhang district, Hangzhou city were selected from a nutritional survey conducted. Peripheral blood lymphocytes were obtained from the study subjects and the demographic information were collected through questionnaires. PCR-restriction fragment length polymorphism (PCR-RFLP) was used for genotyping MDM2 rs2279744 T→G and P53 rs1042522 G→C. Logistic regression analysis was used to analyze the combined effects of the two polymorphisms on breast cancer risk.</p><p><b>RESULTS</b>The frequency of MDM2 rs2279744 GG, TG and TT genotypes were 31.5% (189/600), 45.5% (273/600), 23.0% (138/600) in case group and 19.0% (114/600), 49.2% (295/600), 31.8% (191/600) in control group. The frequency of P53 rs1042522 GG, GC and CC genotypes were 23.1% (139/600), 50.2% (301/600), 26.7% (160/600) in case group and 30.5% (183/600), 51.3% (308/600), 18.2% (109/600) in control group. Logistic regression analysis showed that carriers with rs2279744 TG, GG genotypes had a significant increased risk for developing breast cancer compared with rs2279744 TT carriers (OR = 1.31, 95%CI: 0.97 - 1.73 for TG; OR = 2.24, 95%CI: 1.61 - 3.09 for GG). When comparing with rs1042522 GG carriers, carriers with rs1042522 GC, CC genotypes had a significant increased risk for developing breast cancer (OR = 1.34, 95%CI: 0.94 - 1.68 for GC; OR = 1.89, 95%CI: 1.35 - 2.68 for CC). The united analysis of this two polymorphisms showed that compared with individuals carrying rs2279744 TT and rs1042522 GG (the frequency were 4.8% (29/600) in case group and 11.5% (69/600) in control group), carries with rs2279744 TG/GG and rs1042522 GC/GG genotypes (the frequency were 95.2% (571/600) in case group and 88.5% (531/600) in control group) showed significant higher risk in the susceptibility to breast cancer (OR = 2.30, 95%CI: 1.39 - 3.82 for TG/GC + GG; OR = 2.14, 95%CI: 1.29 - 3.55 for TT + GC/CC; OR = 2.86, 95%CI: 1.80 - 4.53 for TG/GG + GC/CC). The combination of MDM2 rs2279744 T→G and P53 rs1042522 G→C contributed to a significantly higher risk of breast cancer than did any one of the variant (P = 0.046). The risk of susceptibility to breast cancer was much higher when this two polymorphisms both variant.</p><p><b>CONCLUSIONS</b>The MDM2 rs2279744 T→G and P53 rs1042522 G→C may be risk factor for breast cancer. Significant combined effects between the two polymorphisms may contribute to the genetic susceptibility to breast cancer.</p>
Subject(s)
Adult , Female , Humans , Middle Aged , Breast Neoplasms , Genetics , Case-Control Studies , Genetic Predisposition to Disease , Genotype , Polymorphism, Single Nucleotide , Proto-Oncogene Proteins c-mdm2 , Genetics , Risk Factors , Tumor Suppressor Protein p53 , GeneticsABSTRACT
OBJECTIVE: To investigate the effect of galangin on the anti-proliferation and apoptosis of gastric cancer SGC-7901 cells, and possible mechanisms. METHODS: Proliferative activity of SGC-7901 cells was measured by MTT assay while that cell cycle progression and apoptosis of galangin-treated SGC-7901 cells were analyzed by flow cytometry, morphologic observation and mitochondrial membrane potential (MMP) analysis. RESULTSS The evaluated results showed that when galangin was added into cell culture in 40-200 μmol · L-1, proliferative inhibition occurred and was observed as a dose- and time-dependent manner. The calculated IC50 values for galangin were 160, 100 and 70 μmol · L-1 when the treatment time was 24, 48 and 72 h, respectively. Flow cytometry analysis revealed that the proportion of the cells in the G2/M phase was significantly enhanced from 4.40(control group) to 18.31 (treatment group) by a treatment time of 24 h. CONCLUSION: The cells in treatment group showed typical apoptotic morphology and a decrease in MMP. At the same time, the percentage of the apoptotic cells significantly increased from 2.6% or 4.3% (control group) to 27.4% or 65.6% (treatment group), when 160 μmol · L-1 galangin treated SGC-7901 cells for 24 or 48 h. These mentioned results indicate that galangin can inhibit the proliferation and induce apoptosis of the SGC-7901 cells by perturbation in cell cycle progression and mitochondrial dysfunction.